The history and future of targeting cyclin-dependent kinases in cancer therapy
- PMID: 25633797
- PMCID: PMC4480421
- DOI: 10.1038/nrd4504
The history and future of targeting cyclin-dependent kinases in cancer therapy
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4480421/bin/nihms-686151-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4480421/bin/nihms-686151-f0002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4480421/bin/nihms-686151-f0003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4480421/bin/nihms-686151-f0004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4480421/bin/nihms-686151-f0005.gif)
Similar articles
-
An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.Biomed Pharmacother. 2018 Nov;107:1326-1341. doi: 10.1016/j.biopha.2018.08.116. Epub 2018 Aug 29. Biomed Pharmacother. 2018. PMID: 30257348 Review.
-
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.Semin Oncol. 2015 Dec;42(6):788-800. doi: 10.1053/j.seminoncol.2015.09.024. Epub 2015 Sep 24. Semin Oncol. 2015. PMID: 26615126 Review.
-
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275. doi: 10.1016/j.phrs.2016.03.012. Epub 2016 Mar 16. Pharmacol Res. 2016. PMID: 26995305 Review.
-
Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.Expert Opin Investig Drugs. 2006 Jan;15(1):23-38. doi: 10.1517/13543784.15.1.23. Expert Opin Investig Drugs. 2006. PMID: 16370931 Review.
-
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.Pharmacol Res. 2019 Jan;139:471-488. doi: 10.1016/j.phrs.2018.11.035. Epub 2018 Nov 30. Pharmacol Res. 2019. PMID: 30508677 Review.
Cited by
-
DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity.Br J Cancer. 2024 Jul;131(2):243-257. doi: 10.1038/s41416-024-02719-2. Epub 2024 Jun 1. Br J Cancer. 2024. PMID: 38824222
-
ACAT1 promotes proliferation and metastasis of bladder cancer via AKT/GSK3β/c-Myc signaling pathway.J Cancer. 2024 Apr 23;15(11):3297-3312. doi: 10.7150/jca.95549. eCollection 2024. J Cancer. 2024. PMID: 38817856 Free PMC article.
-
Structure-guided design and cloning of peptide inhibitors targeting CDK9/cyclin T1 protein-protein interaction.Front Pharmacol. 2024 May 14;15:1327820. doi: 10.3389/fphar.2024.1327820. eCollection 2024. Front Pharmacol. 2024. PMID: 38808256 Free PMC article.
-
TRIM47 silencing inhibits the malignant biological behaviors of prostate cancer cells by regulating MDM2/p53 signaling.Cell Biochem Biophys. 2024 May 27. doi: 10.1007/s12013-024-01308-7. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 38802602
-
Curdepsidone A Induces Intrinsic Apoptosis and Inhibits Protective Autophagy via the ROS/PI3K/AKT Signaling Pathway in HeLa Cells.Mar Drugs. 2024 May 17;22(5):227. doi: 10.3390/md22050227. Mar Drugs. 2024. PMID: 38786619 Free PMC article.
References
-
- Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nature Med. 1998;4:1103–1106. - PubMed
-
- Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677. - PubMed
-
- Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140:3079–3093. - PubMed
-
- Malumbres M. Therapeutic opportunities to control tumor cell cycles. Clin. Transl. Oncol. 2006;8:399–408. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous